Legend Biotech Corp

LEGN Nasdaq SEC CIK 1801198
Follow Legend Biotech Weekly email: filings, results

Financials

Reported figures only · latest: Q4 2025 USD · IFRS
Revenue, last quarter $306.4M +64.3% vs same quarter last year
Net income −$30.8M −217.2% vs same quarter last year
EPS, diluted -
Operating cash flow −$12.2M +85.1% vs same quarter last year
Revenue by quarter
$94M
$186.5M
$160.2M
$186.5M
$195.1M
$255.1M
$272.3M
$306.4M
Q1 24 Q2 24 Q3 24 Q4 24 Q1 25 Q2 25 Q3 25 Q4 25

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, IFRS
Revenue and net income9 fiscal years
  • Revenue
  • Net income
−$1B−$500M$0$500M$1B$1.5BFY17FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearRevenueNet income
FY25$1B−$296.8M
FY24$627.2M−$177M
FY23$285.1M−$518.3M
FY22$117M−$446.3M
FY21$68.8M−$403.6M
FY20$75M−$266.4M
FY19$60M−$101.6M
FY18$49.1M−$2.8M
FY17--
MarginsShare of revenue
  • Gross margin
  • Operating margin
  • Net margin
−600%−400%−200%0%200%FY17FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearGross marginOperating marginNet margin
FY2561.4%−13.3%−28.8%
FY2465.5%−49.3%−28.2%
FY2349.4%−185.2%−181.8%
FY2244.1%-−381.5%
FY21100%-−586.4%
FY20100%-−355.2%
FY19--−169.4%
FY18--−5.7%
FY17---
Free cash flowOperating cash flow minus capital expenditure
−$600M−$400M−$200M$0$200M$400MFY17FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25−$128.8M
FY24−$158.1M
FY23−$413.4M
FY22−$222.2M
FY21−$240.7M
FY20−$249.3M
FY19−$109.8M
FY18$286.7M
FY17-
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Legend Biotech
  • Healthcare median
−600%−400%−200%0%FY17FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearLegend BiotechHealthcare median
FY25−28.8%−30.6%
FY24−28.2%−47%
FY23−181.8%−58%
FY22−381.5%−80.4%
FY21−586.4%−71.9%
FY20−355.2%−62.2%
FY19−169.4%−46.3%
FY18−5.7%−49.6%
FY17-−45.9%